# A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity

> **NCT00210808** · PHASE2,PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 407 (actual)

## Conditions studied

- Obesity
- Binge-Eating Disorder

## Interventions

- **DRUG:** topiramate

## Key facts

- **NCT ID:** NCT00210808
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** —
- **Final completion:** 2005-03
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2011-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00210808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00210808, "A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00210808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*